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Abstract
Aims: The National Prostate Cancer Audit (NPCA) started in April 2013 with the aim of assessing the process of care and its outcomes in men diagnosed with
prostate cancer in England and Wales. One of the key aims of the audit was to assess the conﬁguration and availability of specialist prostate cancer services in
England.
Materials and methods: In 2014, the NPCA undertook an organisational survey of all 143 acute National Health Service (NHS) Trusts and 48 specialist multi-
disciplinary team (MDT) hubs cross England. Questionnaires established the availability and location of core diagnostic, treatment and patient-centred support
services for the management of non-metastatic prostate cancer in addition to speciﬁc diagnostic and treatment procedures that reﬂect the continuing evolution
of prostate cancer management, such as high-intensity focused ultrasound (HIFU) and stereotactic body radiotherapy.
Results: The survey received a 100% response rate. The results showed considerable geographical variation with respect to the availability of core treatment
modalities, the size of the target population and catchment areas served by specialist MDT hubs, as well as in the uptake of additional procedures and services.
Speciﬁcally there are gaps in the availability of core radiotherapy procedures; high dose rate and low dose rate brachytherapy are available in 44% and 75% of
specialist MDTs, respectively. By comparison, there seems to be a relative ‘over-penetration’ of surgical innovation, with 67% of specialist MDTs providing
robotic-assisted laparoscopic prostatectomy and 21% HIFU. There is also evidence of increased centralisation of core surgical procedures and regional inequity in
the availability of surgical innovation across England.
Conclusions: The organisational survey of the NPCA has provided a comprehensive assessment of the structure and function of specialist MDTs in England and
the availability of prostate cancer procedures and services. As part of the prospective audit, the NPCA will assess the effect of the availability of prostate cancer
services on access regionally and subsequent outcomes of care according to evidence-based guidelines.
 2016 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Cancer services in the National Health Service (NHS)
continue to be developed. In the 1990s, it was recognised
that cancer services were fragmented and poorly organisedAuthor for correspondence: A. Aggarwal, Department of Health Services
Research and Policy, London School of Hygiene and Tropical Medicine,
15e17 Tavistock Place, London WC1H 9SH, UK. Tel: þ44-207-9272135.
E-mail address: ajay.aggarwal@lshtm.ac.uk (A. Aggarwal).
http://dx.doi.org/10.1016/j.clon.2016.02.004
0936-6555/ 2016 The Royal College of Radiologists. Published by Elsevier Lt
creativecommons.org/licenses/by-nc-nd/4.0/).[1]. In response, complex curative treatment services were
concentrated on fewer clinicians within hospitals and these
were required to work together in multidisciplinary teams
(MDTs). Also, a new geographical conﬁguration was estab-
lished, with local cancer units referring complex or rare
cancer conditions to a regional specialist MDT [2,3].
AspecialistprostatecancerMDTcanbeconsideredasahub
made up of one or more specialist centres coordinating ser-
vices for the referring local cancer units.Manyof theprostate
cancer centres also provide services for other urologicald. This is an open access article under the CC BY-NC-ND license (http://
Table 1
List of core and additional procedures and services
Core diagnostic procedures:
 Magnetic resonance imaging
 Multiparametric magnetic resonance imaging
 Isotope bone scan
Additional diagnostic procedures
 Template biopsy
 Choline positron emission tomography
Core treatment procedures
 Radical prostatectomy (open or laparoscopic)
 External beam radiotherapy
 Intensity-modulated radiotherapy
 High dose rate brachytherapy
 Low dose rate brachytherapy
Additional treatment procedures
 Robotic-assisted laparoscopic prostatectomy
A. Aggarwal et al. / Clinical Oncology 28 (2016) 482e489 483malignancies, such as bladder and renal cancer. Through this
set-up, all newly diagnosed patients should have access
within their area to the full range of services required for
comprehensive high-quality cancermanagement.
In 2014, the National Prostate Cancer Audit (NPCA)
(www.npca.org.uk) [4,5] undertook an organisational sur-
vey of NHS cancer units and centres providing care for
prostate cancer patients in England and Wales to describe
the services they provide. The survey examined the pattern
of regional coordination and assessed the availability of core
diagnostic, treatment and patient-centred support services.
It also looked at the availability of speciﬁc additional diag-
nostic and treatment procedures that reﬂect the continuing
evolution of the management of patients with this condi-
tion. Here we present the survey results for England only.
The results for Wales will be published separately. High-intensity focused ultrasound
 Cryotherapy
 Stereotactic body irradiation
Patient-centred support services
 Sexual function services
 Continence services
 Counselling services
 Joint specialist uro-oncology clinicMaterials and Methods
Two questionnaires were developed by the NPCA for the
organisational survey. The ﬁrst questionnaire was directed
at all NHS providers of prostate cancer care (including both
local cancer units and cancer centres) in England with
speciﬁc questions about the availability of diagnostic and
therapeutic procedures and support services. The second
questionnaire was only directed at specialist MDTs. This
questionnaire aimed to obtain information about the
regional coordination of curative treatment services and the
availability of specialist expertise.
The prostate cancer lead for each provider was identiﬁed
and the survey was delivered electronically. Non-
responders were contacted by e-mail and telephone until
a 100% response rate was achieved. During the analysis of
the data, results were clariﬁed with each prostate cancer
lead when necessary. The results presented in this paper
reﬂect the pattern of services as of December 2014, but the
results for named providers, which are being updated
periodically, can be found on the NPCA’s website (www.
npca.org.uk/reports).
For the purpose of this organisational survey, a prostate
cancer centre was deﬁned as an NHS unit that provides
specialist curative (or radical) prostate cancer treatments
(surgery and/or radiotherapy services). We assessed the
availability of core procedures and services in diagnostic,
treatment and patient-centred domains (Table 1). These
core services were chosen as they are included in national
and international guidelines for the management of non-
metastatic prostate cancer [6e8].
Within the patient-centred domain, the provision of a
joint specialist uro-oncology clinic was also included. This
clinic enables patients who are considered to be candidates
for radical treatment to meet both urologists and oncolo-
gists at the same clinic visit e either as a joint consultation
or separate consultations e to discuss treatment options. It
is a measure of service quality according to the English
National Peer Review Programme for cancer services [3].
The survey also assessed the availability of speciﬁc
additional procedures, including transperineal templatebiopsy, choline positron emission tomography imaging,
robotic-assisted laparoscopic prostatectomy, high-intensity
focused ultrasound (HIFU), cryotherapy and stereotactic
body irradiation. These additional procedures are currently
not considered to be part of standard practice according to
most national and international guidelines, but there is
growing evidence supporting their use for particular in-
dications [9e15].
A colour coding system was developed to categorise
specialist MDTs according to the availability of core pro-
cedures and services in the geographical area they cover
[16]. This also accounted for services provided by external
providers that, although outside of this area, provide
selected specialist services to Trusts within the specialist
MDT hub. Specialist MDTs that have all core procedures or
services available within a particular domain were given a
green colour, those not having one core procedure or ser-
vice available an amber colour, and those not having two or
more core procedures or services available a red colour. The
availability of speciﬁc additional diagnostic and treatment
services was graded green if at least one was available and
red if none were available.
The specialist MDTs were subsequently ranked according
to this colour coding system, with the highest weight
assigned to the availability of core diagnostic procedures,
followed by the availability of core treatment procedures
and then followed by the availability of patient-centred
services. Similar colour coding systems have been used for
public reporting of national UK survey data [3,17,18]. Further
ranking was based on the number of additional diagnostic
and treatment procedures available.
At the time of the survey, the 30 English NHS cancer
networks that were responsible for coordination and
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replaced by 27 local area teams across England. The
geographical boundaries of these area teams account for
service patterns and local geographies withinwhich clinical
commissioning groups coordinate the delivery of services
[19]. One or more prostate cancer specialist MDTs are
located within each of the area teams. The availability of
core treatment services within each local area teams was
therefore analysed given that certain services should be
centralised to serve a catchment population of 1e1.5million
people and therefore would not be expected to be provided
by every specialist MDT, e.g. high dose rate brachytherapy.
Survival analyses have been published by the Ofﬁce of Na-
tional Statistics according to NHS area teams [20]. Since
April 2015 the area teams have been replaced by four
regional teams across England (https://www.england.nhs.
uk/about/regional-area-teams/).Results
Conﬁguration of Specialist Multidisciplinary Teams
All NHS providers of prostate cancer services in England
participated in the organisational survey: 143 NHS Trusts
and 48 specialist MDTs. There are, in total, 72 prostate
cancer centres providing radical prostate cancer treat-
ments: 43 provide both surgery and radiotherapy, 18 only
surgery and 11 only radiotherapy. The conﬁguration of
specialist MDTs is complex and the geographical areas they
serve vary in size. The median number of NHS Trusts linked
to a specialist MDT is three, with a range from one to seven.
Some NHS Trusts refer patients to more than one specialist
MDT. This occurs in circumstances where patients live
within the catchment area of two neighbouring specialist
MDTs.
Typically, an area served by a specialist MDT includes one
or two cancer centres providing surgery, radiotherapy or
both. However, we found that there are two specialist MDTs
without a cancer centre in their area that can deliver sur-
gery and 1 specialist MDTs without a cancer centre that can
deliver radiotherapy. These specialist MDTs instead refer
patients to specialist MDTs in adjacent areas for surgical and
radiotherapy procedures. In the results presented below,
these referring specialist MDTs are still considered to pro-
vide these services through their established referral
pathways for specialist services.
Availability of Core Prostate Cancer Services
Specialist MDTs ranked according to the availability of
core procedures and services in diagnostic, treatment and
patient-centred service domains are presented in Table 2.
Only 10 of the 48 specialist MDTs (21%) have all core pro-
cedures and services available in their area (scoring ‘green’
on all three core domains), whereas for 12 specialist MDTs
(25%) at least two core procedures or services are unavai-
lable within one or more domains (scoring ‘red’ for at least
one domain).Forty-four specialist MDTs (92%) have all core diagnostic
procedures available in their area. Multiparametric mag-
netic resonance imaging is not locally available in four
specialist MDTs and isotope bone scanning is also not
locally available in one of these four. Only 16 specialist MDTs
(33%) have all core treatment procedures locally available.
All 48 specialist MDTs provide radical prostatectomy, with
47 providing a laparoscopic approach (robot assisted or
standard). All specialist MDTs provide external beam
radiotherapy either through an NHS Trust within the
specialist MDT or an external provider (11 specialist MDTs
access external beam radiotherapy in this way). The avail-
ability of other core radiotherapy modalities varies:
intensity-modulated radiotherapy is provided by 45
specialist MDTs (94%), low dose rate brachytherapy by 36
(75%) and high dose rate brachytherapy by 21 (44%).
Figure 1 shows the availability of high and low dose rate
brachytherapy across the 27 NHS England local area teams.
Seven local area teams provide only one brachytherapy
modality and are coloured yellow. Four local area teams
have no brachytherapy modalities available and are col-
oured red. It should be noted that in the North Yorkshire
and Humber area team (coloured red), although no high or
low dose rate brachytherapy is available onsite at any of the
Trusts within the region, patients attending York and Har-
rogate NHS Trusts are able to access this routinely through
Leeds University Hospitals NHS Trust, which is based in the
West Yorkshire Area team.
Twenty-ﬁve specialist MDTs (52%) indicated that they
offer a joint specialist uro-oncology clinic. Forty-seven
specialist MDTs (98%) provide sexual function, continence
and counselling services. Continence and counselling ser-
vices are not provided locally in one specialist MDT.
Availability of Additional Diagnostic and Treatment
Procedures
Thirty-four specialist MDTs (71%) provide template bi-
opsy and 31 (65%) choline positron emission tomography,
with 24 (58%) providing both additional diagnostic pro-
cedures. It is important to note that three specialist MDTs
that do not provide multiparametric magnetic resonance
imaging e a core diagnostic procedure e do provide at least
one additional diagnostic procedure.
Thirty-two specialist MDTs (67%) have robotic-assisted
laparoscopic prostatectomy available in their area, 10
(21%) HIFU, eight (16%) cryotherapy and ﬁve (10%) stereo-
tactic body irradiation. No specialist MDT offers all four of
these additional treatments locally, but ﬁve specialist MDTs
offer three. Again, it is noteworthy that 26 of the 32 (81%)
specialist MDTs that do not provide all core treatment
procedures do provide at least one additional treatment
procedure.Discussion
Our survey shows that the organisation of specialist
urological services in the English NHS is complex, with
Table 2
Colour coding of specialist multidisciplinary teams according to the procedures and services they deliver (see text for further details)
Specialist multidisciplinary 
team Number of core procedures and services Number of additional procedures 
Specialist multidisciplinary 
team lead unit
Traffic light core 
diagnostics 
Traffic light for 
core treatments
Traffic light for 
patient-centred 
services 
Additional 
diagnostic
Additional 
treatment
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
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the specialist MDT hub is a hierarchical regional structure
with one cancer centre providing specialist services to two
or more local cancer units in their region serving a target
population of about 1 million people, in keeping with na-
tional guidance [2,3]. However, we found that many
different structures exist.
First, there is a move towards further centralisation, with
currently two specialist MDTs referring to an external can-
cer centre linked to a neighbouring specialist MDT hub for
radical prostatectomy and 11 specialist MDTs referring
externally for radiotherapy modalities.Second, there remain gaps in the availability of core
radiotherapy procedures, such as high and low dose rate
brachytherapy. Current guidelines recommend high dose
rate brachytherapy as an adjunct to external beam radio-
therapy for intermediate and high-risk prostate cancer pa-
tients [21,22]. However, we found that it is only provided by
44% of the specialist MDTs. Low dose rate brachytherapy is
recommended for patients with low- and intermediate-risk
prostate cancer [8,23,24] and it is only provided by 75% of
the specialist MDTs.
Third, the target populations and catchment areas of
specialist MTDs can vary considerably in size. For example,
Fig 1. Availability of high and low dose rate brachytherapy in the 27 National Health Service England local area teams (red ¼ no brachytherapy
modality available; yellow ¼ one brachytherapy modality available; green ¼ both high and low dose rate brachytherapy available).
A. Aggarwal et al. / Clinical Oncology 28 (2016) 482e489486there are four specialist MDTs in Greater Manchester,
together serving a population of about 3 million, whereas
there is only one specialist MDT in North West London
serving a population of about 2 million.
The organisational survey received a 100% response rate
from the clinical leads of the specialist MDTs. An important
limitation of our survey is that it only represents a snap shot
of the conﬁguration of specialist prostate cancer services in
England in December 2014. The provision of services will
continue to evolve, especially following the publication of
the national guidelines in 2014 [8], which highlights the
need to consider updates of the survey results available on
the NPCA’s website (www.npca.org.uk).Another limitation is that we present information on the
availability of procedures and services at the specialist MDT
level and not on how these are being used. However, the
prospective data collection of the NPCAwill ﬁll this gap and
allow an assessment of the effect of differential availability
on access and use of speciﬁc procedures and services.
A third limitation is that the survey uses responses that
were self-reported by the specialist MDTs’ clinical leads.
Therefore, we cannot rule out ‘desirability bias’, pushing
responses towards how the clinical lead wants prostate
cancer care services to be rather than how they actually are.
However, this effect was minimised by only asking factual
information as well as by surveying all individual NHS
A. Aggarwal et al. / Clinical Oncology 28 (2016) 482e489 487Trusts within a particular specialist MDT and seeking clar-
iﬁcation from the clinical leads where inconsistencies in
their responses were observed.
Our results suggest that the uptake of treatment mo-
dalities is not a coordinated process within specialist MDTs,
but is probably driven separately by the urologists and
oncologists within cancer centres. This may explain the
‘over penetration’ of surgical innovation, with 73% (n ¼ 35)
of specialist MDTs providing one ormore additional surgical
procedure (robotic-assisted laparoscopic prostatectomy,
HIFU or cryotherapy) despite only 33% offering all core
radiotherapy modalities, as described above.
Currently, only 11 of the 54 radiotherapy centres in En-
gland provide high dose rate brachytherapy for prostate
cancer. Patients potentially have to travel long distances
(Figure 1) to access this modality, even within local area
teams that have a radiotherapy centre providing low or high
dose rate brachytherapy. Several studies have shown how
increased travel times reduce the uptake of radiotherapy
treatment [25e27]. It remains unknown whether differen-
tial access will lead to inequity in outcomes. However, from
the analysis of existing cancer registry and Hospital Episode
Statistics (HES) data conducted as part of the audit, there is
signiﬁcant national variation observed in the proportion of
high-risk/locally advanced prostate cancer patients
receiving radical therapy [28]. Access to high dose rate
brachytherapy could therefore be a factor.
Commissioning guidelines have been recently published
for high and low dose rate brachytherapy. It is recom-
mended that implantation services be developed on the
basis of a minimum catchment population of 1.5 million and
it is expected that for high dose rate that at least 10 patients
are treated per year in each centre and 50 patients for low
dose rate, with each oncologist performing 25 cases per
year [29]. It is therefore hoped that the cancer strategic
clinical networks will ensure adequate access for patients
with prostate cancer, especially in view of the current dis-
tribution of centres.
The National Institute for Health and Care Excellence
(NICE) have issued guidelines recommending that ‘com-
missioners should ensure that robotic systems for the sur-
gical treatment of localised prostate cancer are cost effective
by basing them in centres that are expected to perform at
least 150 robot-assisted laparoscopic radical prostatec-
tomies per year’ [8]. However, the uptake of robot-assisted
prostatectomy seems to be rapid and follows a pattern
similar to the USA, which has seen a widespread adoption
since the early 2000s, both in high- and low-volume centres
[30], which seems to be driven by hospitals in order to
attract patients [31]. The introduction of a quasi-market
within the English NHS means that patients now have a
choice of where they receive their treatment, which may
explain why a similar process is occurring in England as
centres compete for market share [32]. This will inevitably
reduce the patient volume per unit. It is well known that the
best outcomes are achieved in high-volume units [33].
One way of ensuring that services can be developed
through coordination between urology and oncology teams
is to create closer collaboration between the two specialitiesat the clinical interface. It is recommended that specialist
MDTs have an agreed policy enabling patients with early
(organ-deﬁned) prostate cancer to have access to a joint
specialist uro-oncology clinic where therapeutic options
can be discussed with a urologist, oncologist and a clinical
nurse specialist before a ﬁnal treatment decision is made
[34]. In England, more than half specialist MDTs offer these
specialist clinics. The opportunity for a patient to see both a
urologist and an oncologist at the same clinic visit is
particularly important given the variation that exists be-
tween urologists and oncologists in their recommendations
for the treatment of localised and locally advanced prostate
cancer [35e37].
The results of the organisational survey can also be used
to assess the wider regional variation in the provision of
services in England. For example, since April 2015 the
commissioning and provision of services in the English NHS
has been coordinated by four regional teams: North of En-
gland (16 specialist MDTs), Central and East of England (15
specialist MDTs), London (six specialist MDTs) and South of
England (13 specialist MDTs) (two specialist MDT hubs are
on the boundary of two regions and each is represented in
two regions). There seems to be evidence of regional ineq-
uity in the availability of robotic-assisted prostatectomy.
The percentage of specialist MDTs offering robotic-assisted
prostatectomy in the four regions is 69% in North of En-
gland, 47% in Central and East of England, 100% in London
and 62% in the South of England.
There were also marked differences in the availabilities
of HIFU and cryotherapy, which are treatment modalities
often used for salvage therapy. For example, seven of the
eight specialist MDTs that offer HIFU are based in London
and the South of England. Given their specialist nature,
centralisation of these services to a small number of expert
centres is appropriate, but the reasons for them to be
concentrated in London and the South need to be further
investigated. It may partly reﬂect differences in patient
populations, in particular the way they act as consumers of
care [38e40].
This organisational audit will help to understand the
results of our prospective audit on service use of individual
patients in England andWales [5] as well as informing other
national initiatives [40].Conclusion
The organisational survey of the NPCA has provided a
comprehensive assessment of the structure and function of
specialist MDTs in England and the availability of prostate
cancer procedures and services. Considerable geographical
variation exists, with respect to the availability of core
treatment modalities, the size of target population and
catchment areas, and the uptake of additional procedures
and services.
The NPCA will provide a periodically updated overview
of the organisation of prostate cancer care in England
(www.npca.org.uk/reports), which can inform the further
development of the organisation of prostate cancer services
A. Aggarwal et al. / Clinical Oncology 28 (2016) 482e489488in order to ensure that in the future all newly diagnosed
patients will have access to the cancer treatments and ser-
vices in their local area that are most appropriate for their
speciﬁc needs.Conﬂicts of Interest
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